This oped was first published on Pharma Focus Asia on 2 September 2020.

Reinforcing business integrity 

There is great hope placed in science and in the biopharmaceutical’s industry efforts to find a solution that allows the world to “return to normal”. As the biopharmaceutical industry is at the heart of developing tests, treatments and vaccines and getting them to billions of people around the world, integrity and trust has taken a global stage. From the first days of the COVID-19 pandemic, the industry has been united in its response, acting with urgency and integrity. As a critical participant in the global healthcare ecosystem, we are bringing the full force of our scientific and medical expertise to address the coronavirus pandemic around the world. Society needs to know it can count on the biopharmaceutical industry. We have a responsibility to work tirelessly and rapidly to tap into the industry’s innovation capabilities to bring solutions.

“We at IFPMA have found that our recently launched Ethos has been indispensable in helping provide the necessary framework to anchor ethical decision-making, where no specific rules could have previously been anticipated. As we continue what looks to be a long ride, the need for shaping our actions around the concept of Ethos has never been clearer”, writes Thomas Cueni in an opinion piece for Pharma Focus Asia.

Read more

Author

• 
  Thomas Cueni Director General info@ifpma.org